Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy

Ann Rheum Dis. 2021 Sep;80(9):1243-1245. doi: 10.1136/annrheumdis-2021-220142. Epub 2021 Apr 13.

Francesca Ingegnoli^{1

2}, Gilberto Cincinelli^{3

2}, Angela Flavia Luppino^{3

2}, Ennio Giulio Favalli², Annalisa Orenti^{3

4}, Patrizia Boracchi^{3

4}, Roberto Caporali^{3

2}

¹ Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milano, Italy francesca.ingegnoli@unimi.it.
² Dept of Rheumatology & Clinical Sciences, Clinical Rheumatology Unit, ASST Gaetano Pini-CTO, Milano, Italy.
³ Dept. of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milano, Italy.
⁴ Lab of Medical Statistics, Epidemiology and Biometry GA Maccacaro, Milano, Italy.

No abstract available

Keywords: COVID-19; arthritis; biological therapy; rheumatoid.

Publication types